...
首页> 外文期刊>Journal of Diabetes Science and Technology >GlucoMen Day Continuous Glucose Monitoring System: A Screening for Enzymatic and Electrochemical Interferents
【24h】

GlucoMen Day Continuous Glucose Monitoring System: A Screening for Enzymatic and Electrochemical Interferents

机译:GlucoMen Day连续血糖监测系统:筛选酶和电化学干扰物

获取原文
           

摘要

Background: While most of the common drugs with the potential to interfere with continuous glucose monitoring (CGM) systems are accessible over the counter and can be assumed by CGM patients without medical supervision, many other chemicals are frequently used to treat critically ill patients. Continuous glucose monitoring reading accuracy may also be compromised in patients characterized by abnormally high concentrations of physiological interferents. In this article, 22 species selected from endogenous and exogenous chemicals were screened as possible interferents of GlucoMen?Day (GMD), the new microdialysis-based CGM system from A. Menarini Diagnostics. Method: Interference testing was performed according to the EP7-A2 guideline (Clinical and Laboratory Standards Institute 2005). Interference was evaluated at two levels of glucose, with each interferent additionally tested at two concentrations. Furthermore, two configurations of the GMD disposable sensor kit—one designed for subcutaneous application, the other for direct intravascular CGM—were challenged with interferent-spiked serum and blood samples, respectively. Results: With the exception of dopamine (however, at very high, nonphysiological concentrations), no interference was observed for all the tested substances. Interestingly, none of the common electrochemical interferents (including ascorbic acid, acetaminophen, and salicylic acid, which represent the major specificity issue for the competing CGM systems) significantly affected the system's output. Conclusions: These results provide clear insights into the advantages offered by the use of a microdialysis-based CGM system that additionally relies on the detection of hydrogen peroxide at low operating potential. GlucoMen Day may become the CGM system of choice for those patients who require either regular administration of drugs or their glycemia to be tightly controlled in the intensive care unit or similar environments.
机译:背景:虽然大多数可能干扰连续葡萄糖监测(CGM)系统的常见药物都可以通过柜台获得,并且可以在没有医学监督的情况下由CGM患者服用,但许多其他化学药品经常用于治疗重症患者。对于以异常高浓度的生理干扰素为特征的患者,连续血糖监测的读数准确性也可能会受到影响。在本文中,从内源性和外源性化学物质中筛选出22种,作为A. Menarini Diagnostics基于微透析的新型CGM系统GlucoMen?Day(GMD)的可能干扰物进行了筛选。方法:根据EP7-A2准则(临床和实验室标准协会2005)进行干扰测试。在两种葡萄糖水平下评估干扰,每种干扰素均在两种浓度下进行测试。此外,GMD一次性传感器套件的两种配置(一种设计用于皮下应用,另一种设计用于直接血管内CGM)分别受到了干扰物加标的血清和血液样本的挑战。结果:除了多巴胺(但是,在非常高的非生理浓度下)外,所有被测物质均未观察到干扰。有趣的是,没有一种常见的电化学干扰物(包括抗坏血酸,对乙酰氨基酚和水杨酸,它们代表了竞争性CGM系统的主要特异性问题)不会显着影响系统的输出。结论:这些结果为使用基于微透析的CGM系统提供的优势提供了清晰的见解,该系统还依赖于在低工作电势下检测过氧化氢。对于需要定期服用药物或其血糖在重症监护病房或类似环境中得到严格控制的患者,GlucoMen Day可能成为首选的CGM系统。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号